How to Get a GLP-1 Prescription: Every Legitimate Route

There is no gatekeeper for GLP-1 prescriptions. There is no registry, no specialist referral requirement, and no federal rule saying you must be seen in person first. These drugs are not controlled substances.

What there is instead is a maze of routes that differ enormously in speed, cost, follow-up quality and legitimacy. This guide walks through all six, plus the one that is not a route at all.

Who is allowed to prescribe a GLP-1?

Any clinician licensed to prescribe in your state. That is genuinely the whole answer. Primary care physicians, endocrinologists, obesity medicine specialists, and in most states nurse practitioners and physician assistants can all write for Wegovy, Zepbound, Ozempic or Foundayo.

There is one labeled requirement that applies to everyone who prescribes an injectable. Both the Wegovy and Zepbound labels instruct prescribers to tell patients which presentation they will receive, to train the patient or caregiver on proper injection technique for that specific device before treatment starts, and to retrain if the device changes [1][2]. The Zepbound KwikPen and the Wegovy FlexTouch pen are both flagged as not recommended for self-administration by people who are visually impaired [1][2].

That training requirement is a useful test of a prescribing route. If nobody ever offered you training, something was skipped.

Route 1: your primary care doctor

This is the least glamorous route and often the best one.

A joint review from the Obesity Medicine Association and the American College of Osteopathic Family Physicians describes family physicians as “often the first line of treatment in the healthcare setting,” giving them the earliest chance to intervene [3]. Your primary care clinician already has your chart, your labs, your medication list and your family history, which are exactly the inputs a GLP-1 decision needs.

The same review is honest about the barriers: failure to recognize obesity as a disease, inadequate training, insufficient visit time, weak reimbursement, and weight bias [3]. It also notes that “staff training is often required to navigate the prior authorizations process” [3]. Not every practice has that.

Best for: most people, especially anyone with other conditions or medications in play. Cost: a normal office visit. Watch for: whether the practice actually handles prior authorization, and how long the visit is.

Route 2: an endocrinologist

Endocrinologists specialize in diabetes, thyroid and metabolic disease. They are the conventional referral when type 2 diabetes is involved, when a secondary cause of weight gain is suspected, or when a first drug has not worked.

ADA’s Standards of Care are written largely for this audience, and its 2026 edition names semaglutide or tirzepatide as the preferred pharmacotherapy for people with diabetes and overweight or obesity [4].

Best for: type 2 diabetes, suspected hormonal causes, complex cases. Cost: a specialist visit copay, plus often a referral. Watch for: the wait. New endocrinology appointments are frequently the longest wait of any route.

Route 3: an obesity medicine specialist

Obesity medicine is its own practice area with its own credential.

The Obesity Medicine Association runs a searchable directory of physicians, nurse practitioners, physician assistants and other clinicians with specialized obesity training, filterable by two credentials: ABOM Diplomate and Fellow of the Obesity Medicine Association [5]. An ABOM diplomate has completed at least 60 hours of obesity-specific education and passed the American Board of Obesity Medicine exam; an OMA Fellow has completed at least 75 hours of advanced training [5]. OMA reports more than 5,000 members [3].

These practices typically run longer appointments and combine nutrition, physical activity, behavior therapy and medication, which is the four-pillar model OMA describes [3].

Best for: people who want a structured program, or who have tried and stalled. Cost: varies widely; some are insurance-based, some are cash membership. Watch for: whether the practice bills insurance at all, and whether medication cost is separate from the program fee.

Route 4: telehealth prescribing an FDA-approved brand

Telehealth platforms evaluate you remotely and send a prescription to a retail pharmacy or a manufacturer pharmacy. Because GLP-1s are not controlled substances, there is no federal in-person examination requirement, though state telemedicine and licensure rules still apply.

The access gains are real. A 2026 JMIR analysis reported that in a study of more than 50,000 telehealth participants, weight loss came close to clinical trial benchmarks: 8.9 percent at three months and 19 percent at twelve months [6].

The same analysis flags the catch. Telehealth platforms “don’t always offer nutrition, exercise, and behavioral change guidance required to help patients lose weight safely,” and research finds some patients lose lean tissue and develop micronutrient deficiencies [6]. ADA’s recommendations call for nutrition, physical activity and behavioral therapy alongside medication, ideally with high-frequency counseling of 16 or more sessions over six months [4].

Best for: speed, evenings and weekends, and price transparency. Cost: a consultation or membership fee plus the medicine. Watch for: what follow-up is actually included. Ask directly whether a dietitian is part of the program and how often you will be reassessed.

Route 5: manufacturer direct pharmacies

Both manufacturers now sell their own products directly to cash-paying patients.

Novo Nordisk’s NovoCare Pharmacy dispenses Wegovy and Ozempic, in both pen and tablet form, at published self-pay prices that vary by dose, with home delivery or pharmacy pickup [7]. Eli Lilly’s LillyDirect sells Zepbound and, per Lilly’s approval announcement, Foundayo tablets at published self-pay prices [15].

Two things to understand:

• These channels still require a valid prescription from a licensed prescriber. They are a dispensing route, not a prescribing route. Several telehealth platforms write prescriptions that get filled here.
• They sell the actual FDA-approved product, not a compounded copy.

The important budgeting detail is that self-pay prices are usually set by dose, and the starting dose is often the cheapest. Some ladders also require you to refill within a set window to keep the lower price. Someone who budgets from the starting-dose price will be surprised in month three. Check what your likely maintenance dose costs before you commit.

Best for: people with no coverage, or whose copay exceeds the cash price. Watch for: dose-based pricing, refill windows, and the fact that prices in this market have changed several times a year.

Route 6: Medicare, Medicaid and other public coverage

Medicare Part D has historically excluded drugs used for weight loss, which is why a Medicare beneficiary without type 2 diabetes, cardiovascular disease, sleep apnea or another separately covered indication often had no Part D route at all.

CMS launched the Medicare GLP-1 Bridge on July 1, 2026, a short-term demonstration that runs outside the normal Part D payment flow and offers certain GLP-1 drugs at a flat $50 monthly copay for eligible Part D beneficiaries, currently through December 31, 2027 [8]. CMS has said the end date was extended to December 31, 2027 after the BALANCE Model did not launch for 2027, so the terms have already moved once [8].

Medicare publishes the specifics rather than leaving them vague [14]:

• Covered products: Foundayo tablets, Wegovy injection or tablets, and Zepbound KwikPen only. Single-dose Zepbound vials and pens are not covered.
• Who qualifies: age 18 or older with a BMI of 35 or higher; or a BMI of 30 or higher with diastolic heart failure, uncontrolled hypertension, or chronic kidney disease at stage 3a or higher; or a BMI of 27 or higher with prediabetes, a previous heart attack or stroke, or symptomatic peripheral artery disease.
• Who does not: anyone already getting a GLP-1 covered through their Part D plan, and anyone with type 2 diabetes, moderate-to-severe sleep apnea, or fatty liver disease, because a Part D plan may already cover those uses.
• Mechanics: the prescriber submits a prior authorization and certifies the drug is being used as part of a lifestyle program focused on diet and exercise. An approval is valid through December 31, 2027 unless you switch products.
• The catch on cost: the $50 copay does not count toward your Part D deductible or out-of-pocket limit, cannot be lowered by Extra Help, and cannot be spread across months using the Medicare Prescription Payment Plan.

Medicaid coverage of obesity drugs varies state by state.

Best for: eligible Medicare beneficiaries who previously had no path. Watch for: the exclusions. Having a Part D plan that already covers your GLP-1, or having diabetes, sleep apnea or fatty liver disease, takes you out of the Bridge rather than into it [14].

What is not a legitimate route?

This is the part worth reading twice.

The FDA’s page on unapproved GLP-1 drugs, current as of September 1, 2026, states that “compounded drugs are not FDA approved,” meaning “the agency does not review compounded drugs for safety, effectiveness or quality before they are marketed” [9]. It says semaglutide salt forms such as semaglutide sodium and semaglutide acetate “are different active ingredients than are used in the approved drugs” [9]. It urges consumers not to buy products labeled research-use-only or not for human consumption, which “are of unknown quality and may be harmful to their health” [9].

The FDA has also received “multiple reports of adverse events, some requiring hospitalization, that may be related to dosing errors” when patients measure their own doses [9]. As of May 31, 2026 it had recorded 990 adverse event reports involving compounded semaglutide and more than 730 involving compounded tirzepatide [9].

Separately, the FDA has told telehealth companies that several marketing claims about compounded drugs are false or misleading, including describing a compounded drug as a generic equivalent or identical to an approved version, claiming it received FDA approval or safety evaluation, marketing it as “clinically proven” to match an approved alternative, or saying it comes from an “FDA-approved” or “FDA-licensed” facility, since the FDA does not license pharmacies [10].

And counterfeits are in the real supply chain. The FDA has issued three separate alerts about counterfeit Ozempic: lot NAR0074 in December 2023, which included counterfeit needles with sterility concerns; lot PAR0362 with serial 51746517, in an alert dated April 14, 2025; and lot PAR1229 in December 2025, identifiable because the EXP/LOT text is printed to the left of the expiration date rather than above it [11].

How do I check whether a seller is legitimate?

Run this list before you pay anyone:

1. Is a prescription required? If not, stop.
2. Is it a state-licensed pharmacy? The FDA’s BeSafeRx campaign points consumers to a “Locate a State-Licensed Online Pharmacy” tool for exactly this [12].
3. Is the product the FDA-approved brand? If the site talks about compounded, custom, or personalized semaglutide, you are in a different category with different rules.
4. Does the listing mention a salt form? Semaglutide sodium or semaglutide acetate are not the approved ingredient [9].
5. Does it say “research use only”? That is a red flag the FDA calls out by name [9].
6. Are you being asked to draw your own dose from a vial with no training? The labels require training before initiation [1][2].
7. Is the price far below every published manufacturer self-pay price? That is not a bargain signal in this market.

The FDA also runs MedWatch for reporting side effects and a portal for reporting unlawful online sales [12].

How long will this take?

The prescription is usually not the bottleneck. Insurance is.

Prior authorization is the normal path for this class. The Medicare GLP-1 Bridge requires a prior authorization form from the prescriber, and the provider must also certify that the drug is being used as part of a lifestyle program focused on diet and exercise [14]. On the commercial side, Business Group on Health’s 2026 GLP-1 survey of 105 large employers found that only 67 percent cover GLP-1s for weight management at all, and that those who do use utilization management such as “validating clinical eligibility via objective biometric data, requiring participation in a weight management program to receive coverage, limiting prescribing to specific providers and excluding certain medications from the formulary” [13]. That review takes days to weeks depending on the plan and how complete the submission is. If you want to compress the timeline, the highest-leverage move is finding out what your plan’s criteria are before the appointment, so the prescriber submits a complete packet the first time.

Which route should you pick?

There is no single best route, and any site that ranks providers without disclosing why is not helping you. A reasonable way to decide:

• You have insurance that covers anti-obesity medication: start with primary care, because the prior authorization has to come from a prescriber anyway and your own doctor has the documentation.
• You have no coverage: compare the manufacturer cash price at your likely maintenance dose against a telehealth platform’s all-in monthly cost.
• You have type 2 diabetes or other complex conditions: primary care or endocrinology, not a standalone weight platform.
• You have tried and stalled: an obesity medicine specialist from the OMA or ABOM directories [5].
• You are on Medicare: check the GLP-1 Bridge eligibility rules first, because they determine everything else [8].

Whatever you choose, this article summarizes FDA-approved prescribing information and the Instructions for Use that accompany each product, plus federal and payer coverage rules. It is not advice about whether a GLP-1 is right for you or what dose you should be on. Follow your own prescription, the Instructions for Use supplied with your product, and a healthcare provider who has your full history.

Sources

1. WEGOVY (semaglutide) injection and tablets — US Prescribing Information, DailyMed
2. ZEPBOUND (tirzepatide) injection — US Prescribing Information, Eli Lilly
3. Obesity management in primary care: a joint clinical perspective from the Obesity Medicine Association and ACOFP, Obesity Pillars 2025
4. American Diabetes Association, Section 8: Obesity and Weight Management, Standards of Care in Diabetes–2026
5. Obesity Medicine Association, Find an Obesity Doctor Near You
6. After the Prescription: The Clinical Support Gap in Telehealth-Based GLP-1 Care, JMIR 2026
7. NovoCare Pharmacy
8. CMS, Medicare GLP-1 Bridge
9. FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss
10. FDA, Telehealth Companies: What to Know When Promoting Compounded Drugs
11. FDA Warns Consumers Not to Use Counterfeit Ozempic Found in the US Drug Supply Chain
12. FDA BeSafeRx: Your Source for Online Pharmacy Information
13. Business Group on Health, 2026 GLP-1 survey
14. Medicare.gov, Weight loss drugs — Medicare GLP-1 Bridge
15. Eli Lilly, FDA approves Lilly’s Foundayo (orforglipron), April 1, 2026